Drugs / Autologous B7-H3 CAR T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07509034 | Jul 2026 → Jan 2030 expected | small cell lung carcinoma | National Cancer Institute (NCI) | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous B7-H3 CAR T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07509034 ↗ |
| Action | Deplete | “Chimeric antigen receptor (CAR) T cells recognize and kill target-expressing tumor cells.” NCT07509034 ↗ |
| Modality | Cell therapy | “Chimeric antigen receptor (CAR) T cells recognize and kill target-expressing tumor cells.” NCT07509034 ↗ |
| Route | Intravenous | “The modified T cells will be infused through a vein.” NCT07509034 ↗ |